Figure 1From: PEGylation, increasing specific activity and multiple dosing as strategies to improve the risk-benefit profile of targeted radionuclide therapy with 177Lu-DOTA-bombesin analogues Chemical structures of (a) DOTA-Lys-BN and (b) DOTA-PEG 5k -Lys-BN analogues. Back to article page